News
Lynparza in combination with abiraterone granted priority review in US
AstraZeneca’s supplemental new drug application for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone, has been granted priority review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).